A case of HCC successfully treated with infliximab‐steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy

BACKGROUND: Although reports of gastrointestinal perforation after immune‐related adverse events (irAE) enteritis are rare, the anti‐ vascular endothelial growth factor (VEGF) effect of bevacizumab may be involved in gastrointestinal perforation. We report a rare case of gastrointestinal perforation...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, Satoru, Komeda, Yoriaki, Nishida, Naoshi, Yoshida, Akihiro, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675378/
https://www.ncbi.nlm.nih.gov/pubmed/36224043
http://dx.doi.org/10.1002/cnr2.1721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675378/
https://www.ncbi.nlm.nih.gov/pubmed/36224043
http://dx.doi.org/10.1002/cnr2.1721

Ejemplares similares